 BOSTON, Dec. 06, 2021 GLOBE NEWSWIRE -- TransCode Therapeutics, Inc. Nasdaq: RNAZ today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCodes Chief Executive Officer, Michael Dudley, will describe the Companys RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the companys lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its First in Human clinical trial planned for mid-next year. The presentation will be webcast and an archived recording will be made available in the Investors section of the TransCode Therapeutics website. 